Lytix Biopharma: Second quarter and first half of 2022 results
Lytix Biopharma, a Norwegian immune-oncology company, today releases its second quarter and first half 2022 results – New encouraging clinical data.“The first six months of 2022 have been fueled by clinical development and clinical data presentations across international conferences alongside seeing our partner Verrica Pharmaceuticals advance its Phase II study evaluating LTX-315 for basal cell carcinoma. For Lytix, the most significant clinical trial development was the completion of the Phase II study evaluating LTX-315 in combination with adoptive therapy (ACT) in soft tissue sarcoma